Evidence map›Paper›PMID 37535001›Full record

ArticleAging2023

SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC.

Fengxiao An, Wenjing Zhang, Yuxian Guo, Fuyan Shi, Yujia Kong, Liguo Tang, Caijing Han, Qinghua Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Fengxiao AnDepartment of Clinical Laboratory, Affiliated Hospital of Weifang Medical University, Weifang 261031, Shandong, China.
Wenjing ZhangDepartment of Health Statistics, Key Laboratory of Medicine and Health of Shandong Province, School of Public Health, Weifang Medical University, Weifang 261053, Shandong, China.
Yuxian GuoDepartment of Health Statistics, Key Laboratory of Medicine and Health of Shandong Province, School of Public Health, Weifang Medical University, Weifang 261053, Shandong, China.
Fuyan ShiDepartment of Health Statistics, Key Laboratory of Medicine and Health of Shandong Province, School of Public Health, Weifang Medical University, Weifang 261053, Shandong, China.
Yujia KongDepartment of Health Statistics, Key Laboratory of Medicine and Health of Shandong Province, School of Public Health, Weifang Medical University, Weifang 261053, Shandong, China.
Liguo TangDepartment of Orthopedics, Sunshine Union Hospital, Weifang 261061, Shandong, China.
Caijing HanSchool of Public Health, Weifang Medical University, Weifang 261053, Shandong, China.
Qinghua WangDepartment of Health Statistics, Key Laboratory of Medicine and Health of Shandong Province, School of Public Health, Weifang Medical University, Weifang 261053, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SET binding protein 1 (SETBP1) plays crucial roles in various biological processes; however, its involvement in cancer immune checkpoint inhibitor (ICI) treatments has never been studied. In this study, we collected a total of 631 melanoma and 109 non-small cell lung cancer (NSCLC) samples treated with ICI agents (i.e., anti-CTLA-4, anti-PD-1/PD-L1, or combination therapy). Additionally, we obtained their corresponding somatic mutational profiles. We observed that SETBP1 mutated (SETBP1-MUT) melanoma patients exhibited significantly prolonged ICI survival outcomes compared to wild-type patients (HR: 0.56, 95% CI: 0.38-0.81,

Indexed as

Antineoplastic Agents, ImmunologicalCarcinoma, Non-Small-Cell LungLung NeoplasmsMelanomaBiomarkers, TumorCarrier ProteinsHumansImmune Checkpoint InhibitorsMutationNuclear ProteinsAntineoplastic Agents, ImmunologicalBiomarkers, TumorCarrier ProteinsImmune Checkpoint InhibitorsNuclear ProteinsSETBP1 protein, humanclinical biomarkerICI treatmentmelanomaNSCLCSETBP1 mutation

Identifiers

PMID37535001
PMCPMC10457048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.